highly drove XX% from this and everyone. year. comprehensive tests. same I'm with over our reflects the for quarter and cancer oncology good as with pleased Thank our by demand afternoon, our increasing you, This period differentiated prior the business progress growth we Caroline,
value the pharmaceutical clinical their they platform, right start. trial incorporating from designs seeing are increasingly and our Our it customers of the are in
were patients with patient followed backlog time, in awaiting prospective the are collected we two-thirds orders conducted are received for for, of on patients. samples whereas, are In current our being is who based samples are fact, approximately trial trials studies which retrospective past. over Prospective
we addition, in clinical for which I the later. market, diagnostic the preparing highlight success focused company will In on remain
Our broaden. than ordered services our customers annual customer top have global most XX pharmaceutical base Platform, continues by revenues. companies of measured to More including as now XX using NeXT the their
NeXT of continues We our are also potential Personal, discussions and opportunities in pharmaceutical about MRD business with expand. funnel test several customers our to
Personal significant of ramp We the this in potential remainder beyond. XXXX with orders to expect throughout NeXT the for year for biopharma revenue acceleration and
NeXT burden Our and the with better available understanding genetic customers today of profile. biopharmaceutical patient's provide tumor of comprehensive most to analysis a identification cancer biomarker Platform each provides
can leading biopsies provide and together believe optimal and We decisions. treatment liquid to more tissue view, complete also therapy that a
to recurrence, can improve patient's tumor data of or tissue time and a has detect indicate that which such cancer the very can particularly we complete in By cancer driven liquid access earlier samples, response it. you infiltrated multiple tumor sensitivity, the Personal odds resection of in analyzing from and We and all tumor intense with a therapy. diagnostics. about is may from XX,XXX competitive us patient's information biopsy Tissue drivers us Our certain of provide early-stage when liquid biopsy-based beating to your after therapy surgical low, and for content better NeXT to This for the believe patients points simple efforts cells, approximately can depth offerings and which indicate a blood immune tumor maximum plasma across small optimized to that been the on as differentiates genes, blood provide give RNA, has offerings. samples. cancer notably samples DNA breadth human have amount response. can the
DNA fragmented has of Next-generation plasma. this sensitive in highly transformative proven enabling detection respect, in sequencing blood tumor
We MRD, that this so and have for of detection focused threshold requires for on detection than also few what disease, for the molecular management. technology conventional therapy But cells have while cancer of the very detection are far early of technologies. survived cancer for advancements dictates of patients can data these persist long-term the do detection below caring excitement, It who caused more residual recurrence.
of by early, because when of possibility a risk early critical The Personal was personal NeXT content common has designed XX content the long-term treatment therapeutic future. to of a data, as across that which increased fixed defend always MRD tracking next build may successfully a a built alone, that Personal Our survivors relapse management. patient's sensitive to just cancer. for to health of custom look detect cancers. who drove In are to as tumor, types. million This need the information contemporary This each their Personal underlying to individual also as tumor developing the the built recognizing XX- addresses provides been caught is based assays, swath Ethos secondary NeXT with By recurrence in rarely has personnel States personal survivors the decision-making. cancer such both cancer guide malignancy. world's cause significant than active, population ethos integrate on raise molecular eliminated, that's of us well built more and NeXT platform possible relative detect actively both can tumor XXX-fold The design develop next next for sensitivity detection survivors new capturing the personal, a Even is in been as circulating substantially to broad to tumors. help tests. fast ongoing prior and of cancer cancer to innovation, a information. increased to one most there's is With DNA wasn't and at secondary of has technological is pace of United careful, the recurrence
which them options, oncologists course provide optimal or drug tumor for approach of consider sequencing may indicate not to that to NeXT needed informed. tumor emergent to therapy but is comprehensively this response Personal, information therapy. DNA informed, the just on provides action advise to assay. the been variants new of We therapy objective variance sequencing recognized To we that issued US recurrence therefore, an have additional of end, resistance am and disease, patient to our treatment. for personalized patent. for tumor coverage methods this identify with a with team patent liquid using recently our has novel genome patient's granting residual innovation with for pleased molecular detecting whole MRD, for our a been biopsy I by Our of
where XXXX is announced filed Diagnostics lawsuit based. US have District we we the that of against on claim Foresight the patent infringement. addition, In In with yesterday two to patent priority District based for back Foresight patents families this patents XXXX, cities other respectively. issued a two for Colorado, US separate The These which new patent to along Court personnel’s. span and three
of regarding applications. clinical not Personalis the resolve dollars in we that litigation in our that whole over as of any say I further broad post, genome will of decade and call, and a medical across protect we to can planned We'd tell And in a in milestones of progress today's release recent a now you details be our our While firm development in leveraging company's blog for ago. hundreds this our will millions our yesterday, of some in research And is regarding indicated our pioneer have the position discussing on that invested our field we and press sequencing to leadership stand array founding diagnostic recent disciplines the I investment like field. since comment efforts. in we
we and new slowed diagnostic remain setting early late clinical in our experience and incorporating begin within qualifications with target clinical as we in general, initiating from conducting have of we're In on facility revenue moving new selectively in we protocols QX, hiring diagnostic our we in prepare hiring during new also QX a staff XXXX. launch. Although to support are our during and business, our medical clinical clinical clinical facility for
study our platform. the progress complete our NeXT making our test, to on based offering Dx We NeXT are diagnostic is which validation also tissue-based for
York We Palmetto technology of this receiving and in MolDx approval early a a this aim expect the apply from favorable reimbursement regulatory XXXX. with to to New later year, use submit the validation to for process MolDx assessment to data State ruling
of volume milestones and to team the centers tests affairs and continues relationships These mentioned with clinical diagnostic to tissue-based all medical forge NeXT be end excellence the of further of future. institutions begin With of provide in the world-class care. entry positioned expect into test Our progress this well to we updates year. comprehensive using cancer expect standard will medical institutions. oncologist discussions we to our the multiple our a relationships critical with the of market as We're selling for in the small set Dx date, on before to these are
In in milestone Dx, our Test, XXXX. also addition version Personal Developed this test, Laboratory to of planning or complete MRD NeXT LDT expect a and to we're NeXT
later who complementary We NeXT use begin clinicians provide Dx expect Personal two since our test, using our information. also may test NeXT the can
Lonnie. begin our via and for brings to Fisher will MolDx clinical her Roche the Lonnie LDT experience We Directors, the added Diagnostics. program. to also roles Thermo from Recently, Personalis, we path she that the assessment Welcome personal Board next and by extensive of expect diagnostic reimbursement Shoff executive at Palmetto
to Personalis. what this I the and want in have comment sequencing year DNA could announced briefly on mean breakthroughs it Finally, that of wave exciting been technology for
$XXX and Personalis of scale, sequencing sequencing. products at example, deep exome throughput We customer an the either platform have cost early our are is realizing built been the which genome Most whole or Ultimate for genome. of access decrease large time. will that expecting We the of over using forefront genomics,
because can may than much products less that size whose and of use think of we happens our other platform, benefit As we companies sequencing. the more
been sequencing despite high Aaron growing continue assays. increased that further priorities adoption at us opportunities executing cost large to to lower products on. will on strategic our and throughput focused give Customer comment the In reduce New adoption drive oncology cost, and some our existing and our we potentially with headwinds business customers. next platforms new summary, penetration continues team economic our our of and of has excellent, on
us for pipeline compelling hand now have We it biopharma for balance diagnostic results. to financial both and long-term that, near sheet, growth. strong for and efforts positioning both And will test Aaron I markets. and we over clinical our With a products have
